Takeda Says FDA Approves Treatment for Colorectal Cancer
09 November 2023 - 10:49AM
Dow Jones News
By Stephen Nakrosis
Pharmaceutical company Takeda said Wednesday that the U.S. Food
and Drug Administration approved Fruzaqla as a treatment for
certain patients with colorectal cancer.
Fruzaqla, or fruquintinib, an oral targeted therapy, was
approved for adults with metastatic colorectal cancer who had
received certain previous treatments for the condition.
The company said Fruzaqla and best supportive care showed
"significant improvements in overall survival, with corresponding
improvements in progression free survival, versus placebo plus best
supportive care in two Phase 3 clinical trials."
Data from the trials supported an EU marketing authorization
application for fruquintinib, "which was validated and accepted for
review by the European Medicines Agency in June," Takeda said. A
submission was made in September to the Japan Pharmaceuticals and
Medical Devices Agency, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2023 18:34 ET (23:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From May 2024 to Jun 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Jun 2023 to Jun 2024